Jean Felix Mukerabigwi
Overview
Explore the profile of Jean Felix Mukerabigwi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu Q, Zhang Y, Mukerabigwi J, Wang H, Cao Y
Curr Top Med Chem
. 2024 Jul;
24(13):1101-1119.
PMID: 39005059
This review highlights the advantages of combination therapy using polymer conjugates as drug delivery systems for cancer treatment. In this review, the specific structures and materials of polymer conjugates, as...
2.
Mukerabigwi J, Tang R, Cao Y, Mohammed F, Zhou Q, Zhou M, et al.
Bioconjug Chem
. 2023 Jan;
34(2):377-391.
PMID: 36716444
The multi-drug resistance (MDR) of cancers is one of the main barriers for the success of diverse chemotherapeutic methods and is responsible for most cancer deaths. Developing efficient approaches to...
3.
Ibrahim A, Twizeyimana E, Lu N, Ke W, Mukerabigwi J, Mohammed F, et al.
ACS Appl Bio Mater
. 2022 Jan;
2(11):5099-5109.
PMID: 35021452
High-efficiency endosomal escape of drug delivery nanocarriers for glutathione-based reduction-responsive drug release in cytoplasm can significantly enhance the therapeutic efficacy of the loaded therapeutic drugs. In this report, we develop...
4.
Xu J, Ma M, Mukerabigwi J, Luo S, Zhang Y, Cao Y, et al.
Sci Rep
. 2021 Nov;
11(1):22116.
PMID: 34764340
Recently, a great effort has been made to perfect the therapeutic effect of solid tumor, from single-agent therapy to combined therapy and many other polymer-drug conjugations with dual or more...
5.
Dutta D, Zhou Q, Mukerabigwi J, Lu N, Ge Z
Biomacromolecules
. 2021 Oct;
22(11):4857-4870.
PMID: 34689560
The hypoxia environment inside tumors is tightly associated with tumor growth, metastasis, and drug resistance. However, the heterogonous distribution of hypoxic areas limits the efficacy of hypoxia-activatable drug delivery systems....
6.
Japir A, Ke W, Li J, Mukerabigwi J, Ibrahim A, Wang Y, et al.
J Control Release
. 2021 Oct;
339:418-429.
PMID: 34662586
Combination chemo-immunotherapy of cancers has attracted great attention due to its significant synergistic antitumor effect. The response rates and therapeutic efficacy of immunotherapy can be enhanced significantly after proper combination...
7.
Mukerabigwi J, Han Y, Lu N, Ke W, Wang Y, Zhou Q, et al.
J Mater Chem B
. 2021 Apr;
9(13):3055-3067.
PMID: 33885667
Drug resistance of cisplatin significantly limits its therapeutic efficacy in clinical applications against different cancers. Herein, we develop a novel strategy to overcome cisplatin drug resistance through sensitizing cisplatin-resistant human...
8.
Wang Y, Zhang S, Wang J, Zhou Q, Mukerabigwi J, Ke W, et al.
J Control Release
. 2021 Apr;
333:500-510.
PMID: 33848558
Chemodynamic therapy (CDT) has been proposed to convert tumoral HO into toxic hydroxyl radicals (OH) via Fenton or Fenton-like reactions for antitumor efficacy, which is frequently limited by low HO...
9.
Mohammed F, Ke W, Mukerabigwi J, Japir A, Ibrahim A, Wang Y, et al.
ACS Appl Mater Interfaces
. 2019 Aug;
11(35):31681-31692.
PMID: 31397163
In situ modulation of the surface properties on the micellar drug delivery nanocarriers offers an efficient method to improve the drug delivery efficiency into cells while maintaining stealth and stability...
10.
Mukerabigwi J, Yin W, Zha Z, Ke W, Wang Y, Chen W, et al.
J Control Release
. 2019 Apr;
303:209-222.
PMID: 31026547
Therapeutic nanoreactors are currently emerging as promising nanoplatforms to in situ transform inert prodrugs into active drugs. Nevertheless, it is still challenging to engineer a nanoreactor with balanced key features...